

Amendment B  
U.S. Appl. 09/942,174  
May 11, 2004

Remarks

Claim Amendments

Claims 8-9, 11 and 13 are amended in this Amendment B. Claims 1-7, 12, 14 and 16 are canceled. Upon entry of the amendment, claims 8-11, 13 and 15 will be pending in the application.

Applicants have amended claims 8 and 9 to more particularly define the invention and to improve the form of the claims. No new matter has been added.

Applicants have amended claims 11 and 13 to more particularly define the conditions treated by the methods of the present invention. No new matter has been added. It is respectfully submitted that each of the amended claims is supported in the specification and by canceled claims 12 and 14.

Claims 1-7, 12, 14 and 16 have been cancelled. Applicants reserve the right to pursue any canceled subject matter and/or any other subject matter disclosed in this application in one or more later-filed divisional and/or continuation applications.

*Rejection under 35 U.S.C. §112, first paragraph*

A. Claims 10, 11, 13 and 15 are enabled.

Applicants respectfully request reconsideration of the rejection of claims 10-16 as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains to make and/or use the invention.

In order to be enabled under 35 U.S.C. §112, first paragraph, "the specification must teach those skilled in the art how to make and use the full scope of the claimed invention without 'undue experimentation'." *In re Wright*, 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993). Questions of enablement are evaluated against the claimed subject matter and the first analytical step requires a determination of exactly what subject matter is encompassed by the claims. See, MPEP 2164.08. All that is necessary is that one skilled in the art be able to practice the claimed invention, given the level of knowledge and skill in the art. Further, the scope of enablement must only bear a "reasonable correlation" to the scope of the claims. See, e.g., *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).

Amendment B  
U.S. Appl. 09/942,174  
May 11, 2004

In the instant case, the Examiner maintains her rejection on the premise that the claims, which are directed to the treatment of tumor metastasis, tumor growth and solid tumor growth, are not enabled for every type of "tumor." However, Applicants respectfully point out that claim 11 as amended provides a method for treating  $\alpha_v\beta_3$ -mediated tumor metastasis,  $\alpha_v\beta_3$ -mediated tumor growth and  $\alpha_v\beta_3$ -mediated solid tumor growth rather than merely tumor metastasis, tumor growth and solid tumor growth generally. As described at page 1, lines 20 to 32 of the specification, it is well known within the art of oncology that the  $\alpha_v\beta_3$  integrin "plays a role in various conditions or disease states including tumor metastasis, solid tumor growth (neoplasia), osteoporosis (Ross et al., *J. Biol. Chem.*, 1987, 262, 7703), Paget's disease, humoral hypercalcemia of malignancy (Caron et al., *Cancer Res.* 1998, 58, 1930), osteopenia (Lark et al., *J Bone Miner. Res.* 2001, 16, 319), endometriosis (Healy et al., *Hum. Reproductive Update*, 1998, 4, 736), angiogenesis, including tumor angiogenesis (Cheresh, *Cancer Metastasis Rev.*, 1991, 10, 3-10 and Brooks et al., *Cell*, 1994, 79, 1157), retinopathy including macular degeneration (Friedlander et al., *Proc. Natl. Acad. Sci USA* 1996, 93, 9764), arthritis, including rheumatoid arthritis (Badger et al., *Arthritis Rheum.*, 2001, 44, 128), periodontal disease, psoriasis and smooth muscle cell migration (e.g. restenosis) and atherosclerosis (Brown et al., *Cardiovascular Res.*, 1994, 28, 1815)." Likewise, amended claim 13 provides a method for treating  $\alpha_v\beta_5$ -mediated tumor metastasis,  $\alpha_v\beta_5$ -mediated tumor growth and  $\alpha_v\beta_5$ -mediated solid tumor growth. As described at page 2, lines 6 to 12 of the specification, "the integrin  $\alpha_v\beta_5$  plays a role in neovascularization. Antagonists of the  $\alpha_v\beta_5$  integrin will inhibit neovascularization and will be useful for treating and preventing angiogenesis, metastasis, tumor growth, macular degeneration and diabetic retinopathy." Accordingly, one of ordinary skill in the art of oncology would be able to practice the invention as claimed because the claims as amended are directed to  $\alpha_v\beta_3$ -mediated conditions and  $\alpha_v\beta_5$ -mediated conditions respectfully. As such, claims 11 and 13 are not so broad as to lack enablement under 35 U.S.C. §112, first paragraph.

Claim 10 is directed to a pharmaceutical composition. It is respectfully submitted that claim 10 is enabled by the description at pages 27-28 of the specification.

Claim 15 is directed to a method for treating neoplasia using a combination of the antagonists of the present invention with known chemotherapeutic agents. It is respectfully submitted that the standard treatment of various solid tumors using various chemotherapeutic

Amendment B  
U.S. Appl. 09/942,174  
May 11, 2004

agents is well known in the art. As such, the scope of the claim is not overly broad such that one skilled in the art would be able to combine the standards of treatment for a given neoplasia and the compounds of the present invention to practice the present invention.

Because the scope of the claims as amended is commensurate in scope with the teachings in the specification and the general knowledge available to one of ordinary skill in the art, it is respectfully submitted that claims 10, 11, 13 and 15 are sufficiently enabled under 35 U.S.C. §112, first paragraph. Reconsideration and withdrawal of the rejection is respectfully requested.

*Previous Rejections under 35 U.S.C. §112, first paragraph*

Applicants acknowledge the withdrawal of rejections labeled a), b), c) and e) of the previous office action.

**D. Definitions of X**

Claim 8 is amended to include X<sup>7</sup> and X<sup>8</sup> to overcome the rejection as described in the previous response filed October 8, 2003.

**F. Definiteness of Claim 9**

Claim 9 is amended to correct the open bracket and overcome the rejection.

**G. Definiteness of Claims 10-16**

Claims 10-16 are rejected for alleged indefiniteness as requiring undue experimentation to determine the scope of the claims. However, as described above with respect to the rejection under 35 U.S.C. §112, first paragraph, Applicants respectfully submit that amended claims 10, 11, 13 and 15 are sufficiently clear such that one skilled in the art would be able to practice the present invention. Accordingly, it is respectfully submitted that the claims satisfy the requirements of 35 U.S.C. §112, second paragraph.

**H. Definiteness of Claim 15**

Claim 15 is rejected because the term "chemotherapeutic agent" is indefinite. However, Applicants respectfully submit that the term "chemotherapeutic agent" is sufficiently clear to be

Amendment B  
U.S. Appl. 09/942,174  
May 11, 2004

understood by one of ordinary skill in the art. Breadth of a claim is not to be equated with indefiniteness. *In re Miller*, 441 F.2d 689, 169 USPQ 597 (CCPA 1971). "If the scope of the subject matter embraced by the claims is clear, and if applicants have not otherwise indicated that they intend the invention to be of a scope different from that defined in the claims, then the claims comply with 35 U.S.C. §112, second paragraph." MPEP 2173.04. Accordingly, claim 15 satisfies 35 U.S.C. §112, second paragraph.

**I. Claim 16**

Claim 16 has been canceled, thereby mooting the rejection.

*Rejections under 35 U.S.C. §102*

Applicants gratefully acknowledge withdrawal of the rejections under 35 U.S.C. §102.

*New Rejections under 35 U.S.C. §112, first paragraph*

**A. Haloalky**

Claim 8 has been amended to replace the term "haloalky" with "haloalkyl."

**B. Z1 on A-B ring**

The depiction of Z<sup>1</sup> on the A-B ring has been amended to more clearly indicate that Z<sup>1</sup> is a divalent moiety. The depiction includes Z<sup>1</sup> to show its position relative to the A-B ring; however, Z<sup>1</sup> remains bonded to Z<sup>2</sup> as shown in Formula I.

**C. R<sup>79</sup> and R<sup>81</sup>**

The definitions of -OR substituents in the A1 moieties of claim 8 have been amended to overcome the rejection and to more clearly indicate that R (now designated as R<sup>8</sup>) may be H, alkyl or amino.

**D. B and R<sup>4</sup>**

Claim 8 has been amended to replace B and R4 with the correct designations of B<sup>4</sup> and R<sup>79</sup> respectively.

Amendment B  
U.S. Appl. 09/942,174  
May 11, 2004

**E. B4**

The rejection is obviated by the correction of B<sup>4</sup> and R<sup>79</sup> stated above.

*Provisional Double Patenting Rejection*

Claims 8-16 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting over the claims of application serial number 10/363,070. Because no subject matter of either application has yet been found to be allowable, Applicants submit that this rejection is premature. Applicants will address the rejection to the extent necessary once the claims have been found to be otherwise allowable.

*Conclusion*

It is believed that the present application is in condition for allowance. Thus, prompt and favorable consideration of this amendment is respectfully requested. If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (314) 446-7683.

Applicants do not believe that any fee is required by the timely submission of this response. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 08-0750. Further, if there is any other fee deficiency or overpayment of any fees in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or credit such overpayment to Deposit Account No. 08-0750.


Respectfully submitted,



James E. Davis, PTO Reg. No. 47,516  
Harness, Dickey & Pierce, LLC  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500 (general tel)  
(314) 446-7683 (direct tel)  
(314) 726-7501 (fax)

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to Examiner Brenda Libby Coleman, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 at facsimile no. 703-872-9306 on May 11, 2004.



Signature

Peggy Marie Leslie  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Amendment B (12 pages)  
Fax Cover Sheet (1 page)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*